Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

A Multicomponent Intervention to Encourage Stair Use in Municipal Buildings.

Moloughney BW, Bursey GE, Fortin RB, Morais MG, Dang KT.

Am J Health Promot. 2018 Jan 1:890117118776893. doi: 10.1177/0890117118776893. [Epub ahead of print]

PMID:
29772921
2.

Aerial Mobile Radiation Survey Following Detonation of a Radiological Dispersal Device.

Sinclair LE, Fortin R, Buckle JL, Coyle MJ, Van Brabant RA, Harvey BJ, Seywerd HC, McCurdy MW.

Health Phys. 2016 May;110(5):458-70. doi: 10.1097/HP.0000000000000491.

PMID:
27023033
3.

Aging Reduces the Activation of the mTORC1 Pathway after Resistance Exercise and Protein Intake in Human Skeletal Muscle: Potential Role of REDD1 and Impaired Anabolic Sensitivity.

Francaux M, Demeulder B, Naslain D, Fortin R, Lutz O, Caty G, Deldicque L.

Nutrients. 2016 Jan 15;8(1). pii: E47. doi: 10.3390/nu8010047.

4.

I WAS HERE: young mothers who have experienced homelessness use Photovoice and participatory qualitative analysis to demonstrate strengths and assets.

Fortin R, Jackson SF, Maher J, Moravac C.

Glob Health Promot. 2015 Mar;22(1):8-20. doi: 10.1177/1757975914528960. Epub 2014 May 15.

PMID:
24830441
5.

Enhancing clinical decision support to improve appropriate antimicrobial use.

Beaulieu J, Fortin R, Palmisciano L, Elsaid K, Collins C.

Am J Health Syst Pharm. 2013 Jul 1;70(13):1103-4, 1113. doi: 10.2146/ajhp120589. No abstract available.

PMID:
23784157
6.

Strengthening chronic disease prevention programming: the Toward Evidence-Informed Practice (TEIP) Program Assessment Tool.

Albert D, Fortin R, Lessio A, Herrera C, Riley B, Hanning R, Rush B.

Prev Chronic Dis. 2013 May 30;10:E88. doi: 10.5888/pcd10.120106.

7.

Strengthening chronic disease prevention programming: the Toward Evidence-Informed Practice (TEIP) Program Evidence Tool.

Albert D, Fortin R, Herrera C, Riley B, Hanning R, Lessio A, Rush B.

Prev Chronic Dis. 2013 May 30;10:E87. doi: 10.5888/pcd10.120107.

8.

Aerial measurement of radioxenon concentration off the west coast of Vancouver Island following the Fukushima reactor accident.

Sinclair LE, Seywerd HC, Fortin R, Carson JM, Saull PR, Coyle MJ, Van Brabant RA, Buckle JL, Desjardins SM, Hall RM.

J Environ Radioact. 2011 Nov;102(11):1018-23. doi: 10.1016/j.jenvrad.2011.06.008. Epub 2011 Jul 13.

PMID:
21745702
9.

Identification of a new biaryl scaffold generating potent renin inhibitors.

Lacombe P, Aspiotis R, Bayly C, Chen A, Dubé D, Fortin R, Gallant M, Juteau H, Liu S, McKay D, Roy P, Wu T.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5822-6. doi: 10.1016/j.bmcl.2010.07.127. Epub 2010 Aug 3.

PMID:
20728350
10.

Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.

Burch JD, Belley M, Fortin R, Deschênes D, Girard M, Colucci J, Farand J, Therien AG, Mathieu MC, Denis D, Vigneault E, Lévesque JF, Gagné S, Wrona M, Xu D, Clark P, Rowland S, Han Y.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2048-54. doi: 10.1016/j.bmcl.2008.01.103. Epub 2008 Jan 31.

PMID:
18291643
11.

Blood serum proteome for welfare evaluation in pigs.

Roncada P, Begni B, Amadori M, Cristoni S, Archetti IL, Boldetti C, Fortin R, Deriu F, Greppi GF.

Vet Res Commun. 2007 Aug;31 Suppl 1:321-5. No abstract available.

PMID:
17682905
12.

Differential expression and secretion of alpha1-acid glycoprotein in bovine milk.

Ceciliani F, Pocacqua V, Lecchi C, Fortin R, Rebucci R, Avallone G, Bronzo V, Cheli F, Sartorelli P.

J Dairy Res. 2007 Aug;74(3):374-80.

PMID:
17692138
13.

Solid-phase analogue synthesis of caspase-3 inhibitors via palladium-catalyzed amination of 3-bromopyrazinones.

Isabel E, Aspiotis R, Black WC, Colucci J, Fortin R, Giroux A, Grimm EL, Han Y, Mellon C, Nicholson DW, Rasper DM, Renaud J, Roy S, Tam J, Tawa P, Vaillancourt JP, Xanthoudakis S, Zamboni RJ.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1671-4. Epub 2007 Jan 11.

PMID:
17251019
14.

Proteomic evaluation of milk from different mammalian species as a substitute for breast milk.

D'Auria E, Agostoni C, Giovannini M, Riva E, Zetterström R, Fortin R, Greppi GF, Bonizzi L, Roncada P.

Acta Paediatr. 2005 Dec;94(12):1708-13.

PMID:
16421029
15.

A proteomic approach to investigate immunity against R. Equi in foals.

Roncada P, Bonizzi L, Fortin R, Menandro ML, Greppi GF.

Vet Res Commun. 2005 Aug;29 Suppl 2:215-9. No abstract available.

PMID:
16244959
16.

Acrylamide-agarose copolymers: improved resolution of high molecular mass proteins in two-dimensional gel electrophoresis.

Roncada P, Cretich M, Fortin R, Agosti S, De Franceschi L, Greppi GF, Turrini F, Carta F, Turri S, Levi M, Chiari M.

Proteomics. 2005 Jun;5(9):2331-9.

PMID:
15887187
17.

The prodrug activator EtaA from Mycobacterium tuberculosis is a Baeyer-Villiger monooxygenase.

Fraaije MW, Kamerbeek NM, Heidekamp AJ, Fortin R, Janssen DB.

J Biol Chem. 2004 Jan 30;279(5):3354-60. Epub 2003 Nov 10.

18.

Structure and function of human erythrocyte pyruvate kinase. Molecular basis of nonspherocytic hemolytic anemia.

Valentini G, Chiarelli LR, Fortin R, Dolzan M, Galizzi A, Abraham DJ, Wang C, Bianchi P, Zanella A, Mattevi A.

J Biol Chem. 2002 Jun 28;277(26):23807-14. Epub 2002 Apr 17.

19.

The allosteric regulation of pyruvate kinase.

Valentini G, Chiarelli L, Fortin R, Speranza ML, Galizzi A, Mattevi A.

J Biol Chem. 2000 Jun 16;275(24):18145-52.

20.

2-heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors.

Dubé D, Brideau C, Deschênes D, Fortin R, Friesen RW, Gordon R, Girard Y, Riendeau D, Savoie C, Chan CC.

Bioorg Med Chem Lett. 1999 Jun 21;9(12):1715-20.

PMID:
10397507
21.

2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.

Friesen RW, Brideau C, Chan CC, Charleson S, Deschênes D, Dubé D, Ethier D, Fortin R, Gauthier JY, Girard Y, Gordon R, Greig GM, Riendeau D, Savoie C, Wang Z, Wong E, Visco D, Xu LJ, Young RN.

Bioorg Med Chem Lett. 1998 Oct 6;8(19):2777-82.

PMID:
9873621
22.

Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.

Delorme D, Ducharme Y, Brideau C, Chan CC, Chauret N, Desmarais S, Dubé D, Falgueyret JP, Fortin R, Guay J, Hamel P, Jones TR, Lépine C, Li C, McAuliffe M, McFarlane CS, Nicoll-Griffith DA, Riendeau D, Yergey JA, Girard Y.

J Med Chem. 1996 Sep 27;39(20):3951-70.

PMID:
8831761
23.

Microsomal metabolism of the 5-lipoxygenase inhibitors L-746,530 and L-739,010 to reactive intermediates that covalently bind to protein: the role of the 6,8-dioxabicyclo[3.2.1]octanyl moiety.

Chauret N, Nicoll-Griffith D, Friesen R, Li C, Trimble L, Dubé D, Fortin R, Girard Y, Yergey J.

Drug Metab Dispos. 1995 Dec;23(12):1325-34.

PMID:
8689939
24.

Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816.

Hutchinson JH, Riendeau D, Brideau C, Chan C, Delorme D, Denis D, Falgueyret JP, Fortin R, Guay J, Hamel P, et al.

J Med Chem. 1993 Sep 17;36(19):2771-87.

PMID:
8410991
25.

Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.

Brideau C, Chan C, Charleson S, Denis D, Evans JF, Ford-Hutchinson AW, Fortin R, Gillard JW, Guay J, Guévremont D, et al.

Can J Physiol Pharmacol. 1992 Jun;70(6):799-807.

PMID:
1330258
26.

5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.

Evans JF, Lévillé C, Mancini JA, Prasit P, Thérien M, Zamboni R, Gauthier JY, Fortin R, Charleson P, MacIntyre DE, et al.

Mol Pharmacol. 1991 Jul;40(1):22-7.

PMID:
1857337
27.

Identification and isolation of a membrane protein necessary for leukotriene production.

Miller DK, Gillard JW, Vickers PJ, Sadowski S, Léveillé C, Mancini JA, Charleson P, Dixon RA, Ford-Hutchinson AW, Fortin R, et al.

Nature. 1990 Jan 18;343(6255):278-81.

PMID:
2300172
28.

Sensitivity to "atypical" mycobacteria in high school children in two community health departments.

Frappier-Davignon L, Fortin R, Desy M.

Can J Public Health. 1989 Sep-Oct;80(5):335-8.

PMID:
2509059
29.

L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.

Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Denis D, Foster A, Fortin R, Leger S, McFarlane CS, Morton H, et al.

Can J Physiol Pharmacol. 1989 May;67(5):456-64.

PMID:
2548691
30.

The use of synthetic thromboxane A2 (TXA2-S) and a new class of thromboxane antagonists, indole-2-propanoic acids to characterize the thromboxane receptor.

Gillard JW, Morton HE, Fortin R, Yoakim C, Girard Y, Lord A, Ethier D, Leveille C, Letts G, Evans J, et al.

Prog Clin Biol Res. 1989;301:579-83. No abstract available.

PMID:
2529557
31.

Behavioral influences of rectal diazepam in solution on dental patients with mentally and physically handicapping conditions.

Diner MH, Fortin RC, Marcoux P, Legault V.

Spec Care Dentist. 1988 Jan-Feb;8(1):19-22.

PMID:
2978761
32.

Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist.

Hall RA, Gillard J, Guindon Y, Letts G, Champion E, Ethier D, Evans J, Ford-Hutchinson AW, Fortin R, Jones TR, et al.

Eur J Pharmacol. 1987 Mar 17;135(2):193-201.

PMID:
3582493
33.

Novel arylthio- and arylsulfonylpropyloxyacetophenones: design and synthesis of L-648,051 and L-649,923, potent antagonists of leukotriene D4.

Young RN, Jones TR, Atkinson JG, Bélanger P, Champion E, Denis D, DeHaven RN, Ford-Hutchinson AW, Fortin R, Frenette R, et al.

Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:544-8. No abstract available.

PMID:
2959111
34.

L-648,051: an aerosol active leukotriene D4 receptor antagonist.

Jones TR, Guindon Y, Champion E, Charette L, DeHaven RN, Denis D, Ethier D, Ford-Hutchinson AW, Fortin R, Frenette R, et al.

Adv Prostaglandin Thromboxane Leukot Res. 1987;17B:1012-7. No abstract available.

PMID:
2823551
35.

L-648,051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)- propylsulfonyl]-gamma-oxo-benzenebutanoate: a leukotriene D4 receptor antagonist.

Jones TR, Guindon Y, Young R, Champion E, Charette L, Denis D, Ethier D, Hamel R, Ford-Hutchinson AW, Fortin R, et al.

Can J Physiol Pharmacol. 1986 Dec;64(12):1535-42.

PMID:
3030524
36.

Design and synthesis of sodium (beta R*, gamma S*)-4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl] thio]-gamma-hydroxy-beta-methylbenzenebutanoate: a novel, selective, and orally active receptor antagonist of leukotriene D4.

Young RN, Bélanger P, Champion E, DeHaven RN, Denis D, Ford-Hutchinson AW, Fortin R, Frenette R, Gauthier JY, Gillard J, et al.

J Med Chem. 1986 Sep;29(9):1573-6. No abstract available.

PMID:
3746809
37.

L-649,923, sodium (beta S*, gamma R*-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio)-gamma-hydroxy -beta-methylbenzenebutanoate. A selective, orally active leukotriene D4 receptor antagonist.

Young RN, Guindon Y, Jones TR, Ford-Hutchinson AW, Bélanger P, Champion E, Charette L, DeHaven RN, Denis D, Fortin R, et al.

Adv Prostaglandin Thromboxane Leukot Res. 1986;16:37-45. No abstract available.

PMID:
3028100
38.
39.

Delayed thrombolysis of streptokinase-resistant occlusive thrombus: documentation by pre- and postmortem coronary angiography.

Isner JM, Konstam MA, Fortin RV, Lefebvre M, Salem DN.

Am J Cardiol. 1983 Jul;52(1):210-1. No abstract available.

PMID:
6858915
41.

Condylomatous lesions of the cervix. II. Cytologic, colposcopic and histopathologic study.

Meisels A, Fortin R, Roy M.

Acta Cytol. 1977 May-Jun;21(3):379-90. No abstract available.

PMID:
268117
42.

Condylomatous lesions of the cervix and vagina. I. Cytologic patterns.

Meisels A, Fortin R.

Acta Cytol. 1976 Nov-Dec;20(6):505-9.

PMID:
1069445
43.

Negative salience in impressions of character: effects of unequal proportions of positive and negative information.

Richey MH, Koenigs RJ, Richey HW, Fortin R.

J Soc Psychol. 1975 Dec;97(Second Half):233-41. No abstract available.

PMID:
1207090
44.

Genital tuberculosis: cytologic detection.

Meisels A, Fortin R.

Acta Cytol. 1975 Jan-Feb;19(1):79-81. No abstract available.

PMID:
803746
45.

Rhinosporidiosis.

Fortin R, Meisels A.

Acta Cytol. 1974 Mar-Apr;18(2):170-3. No abstract available.

PMID:
4523819
46.

[Mallory's hyaline degeneration in an unusual location].

Fortin R.

Ann Anat Pathol (Paris). 1973 Oct-Dec;18(4):459-62. French. No abstract available.

PMID:
4793237
47.

[Halothane-induced hepatitis].

Fortin R, Fouquette B.

Ann Anat Pathol (Paris). 1973 Jul-Sep;18(3):301-8. French. No abstract available.

PMID:
4780415
48.

[Arthrodesis of the knee with a long Küntscher nail].

Cloutier JM, Fortin R.

Union Med Can. 1972 Sep;101(9):1842-6. French. No abstract available.

PMID:
5075016
49.

[Spontaneous interstitial renal reflux due to ureteral reflux demonstrated during intravenous urography. Study of 4 patients].

Fortin R, Coulonval L.

Ann Radiol (Paris). 1972 Jan-Feb;15(1):19-26. French. No abstract available.

PMID:
5025348
50.

[Efficiency of the mobile teams for the point of view of the patients, the region and the teams themselves].

Messier M, Fortin R, Bouchard C, Lazar L.

Laval Med. 1971 Dec;42(10):1010-6. French. No abstract available.

PMID:
5143868

Supplemental Content

Loading ...
Support Center